Ozempic vs Zepbound (2026): Which GLP-1 Is Better for Weight Loss?
Ozempic vs Zepbound (2026): Which GLP-1 Is Better for Weight Loss?
Medically reviewed by Telehealth Ally Medical Review Team. Pricing and protocol data last verified April 2026.
Ozempic and Zepbound are the two most-searched injectable GLP-1 medications for weight loss, but they are not equivalent — and comparing them directly requires understanding why the distinction matters clinically, financially, and for insurance coverage.
Zepbound produces substantially more weight loss than Ozempic and is FDA-approved for that purpose. Ozempic is a diabetes drug used off-label for weight loss. In the first head-to-head trial, tirzepatide (Zepbound) produced 47% greater relative weight loss than semaglutide over 72 weeks.
What is the fundamental difference between Ozempic and Zepbound?
Ozempic (semaglutide) and Zepbound (tirzepatide) are different molecules with different mechanisms — not the same drug with different labels. Ozempic is a GLP-1 receptor agonist approved for type 2 diabetes. Zepbound is a dual GLP-1/GIP receptor agonist approved for chronic weight management. The dual mechanism of tirzepatide is believed to explain its superior weight loss outcomes.
| Ozempic | Zepbound | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| FDA-approved for | Type 2 diabetes | Chronic weight management |
| Max dose | 2.0mg/week | 15mg/week |
| Year approved | 2017 | 2023 |
| Weight loss indication | Off-label only | On-label |
The "same drug, different label" pattern applies to Ozempic/Wegovy (both semaglutide) and to Mounjaro/Zepbound (both tirzepatide) — but not to Ozempic vs Zepbound. These are genuinely different molecules.
How does the mechanism of Ozempic vs Zepbound differ?
Ozempic activates one receptor; Zepbound activates two.
Ozempic (semaglutide — GLP-1 only):
- Mimics the GLP-1 incretin hormone
- Reduces appetite by acting on hunger centers in the brain
- Slows gastric emptying, increasing satiety
- Improves insulin sensitivity and blood sugar regulation
Zepbound (tirzepatide — GLP-1 + GIP):
- Activates all of the above via GLP-1 receptor
- Additionally activates GIP (glucose-dependent insulinotropic polypeptide) receptors
- GIP activation enhances insulin secretion, may improve fat metabolism, and appears to amplify appetite suppression beyond GLP-1 alone
- First medication of its class (dual incretin agonist)
The GIP receptor component is believed to explain tirzepatide's greater weight loss efficacy compared to semaglutide, though research into the exact mechanism is ongoing.
What do the clinical trials show for Ozempic vs Zepbound weight loss?
In the SURMOUNT-5 head-to-head trial (2024), tirzepatide produced 20.2% mean body weight loss compared to 13.7% for semaglutide — a 47% greater relative weight reduction over 72 weeks. This is the most important data point for patients comparing the two options.
Semaglutide weight loss evidence
Note: Ozempic's clinical trials (SUSTAIN series) were designed primarily for diabetes management, with weight loss as a secondary endpoint. For accurate semaglutide weight loss data, the Wegovy (semaglutide 2.4mg) trials are more relevant:
| Trial | Drug/Dose | Duration | Mean Weight Loss |
|---|---|---|---|
| STEP 1 (NEJM 2021) | Semaglutide 2.4mg | 68 weeks | 14.9% |
| STEP 5 (Nat Med 2022) | Semaglutide 2.4mg | 104 weeks | 15.2% |
| SUSTAIN 1 (Ozempic 1.0mg) | Semaglutide 1.0mg | 30 weeks | ~4.5kg |
Ozempic's maximum dose is 2.0mg/week — lower than Wegovy's weight-loss-optimized 2.4mg. Patients using Ozempic off-label for weight loss are using a lower dose than the drug developed specifically for that purpose.
Tirzepatide weight loss evidence
| Trial | Dose | Duration | Mean Weight Loss |
|---|---|---|---|
| SURMOUNT-1 (NEJM 2022) | 5mg | 72 weeks | 16.0% |
| SURMOUNT-1 (NEJM 2022) | 10mg | 72 weeks | 21.4% |
| SURMOUNT-1 (NEJM 2022) | 15mg | 72 weeks | 22.5% |
| SURMOUNT-2 (Lancet 2023) | 15mg (with T2D) | 72 weeks | 14.7% |
| SURMOUNT-5 vs semaglutide | 15mg | 72 weeks | 20.2% (vs 13.7%) |
Even tirzepatide's lowest dose (5mg, 16.0% weight loss) outperformed semaglutide's best weight loss results in trial data. At the 15mg maintenance dose, over 1 in 3 SURMOUNT-1 participants lost ≥25% of body weight.
How do Ozempic and Zepbound compare on FDA indications?
FDA indications determine what insurance will cover and what prescribing is on-label versus off-label.
Ozempic FDA indication: Type 2 diabetes management, with reduction of major cardiovascular events in adults with T2D and established cardiovascular disease. Weight loss is explicitly off-label for Ozempic.
Zepbound FDA indication: Chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, obstructive sleep apnea, cardiovascular disease). This is the on-label use.
If weight loss is your primary goal and you don't have type 2 diabetes, Zepbound is the clinically appropriate drug. Prescribing Ozempic for weight loss in a patient without T2D is off-label, which affects insurance coverage and puts the patient on a lower dose than the weight-loss-optimized equivalent (Wegovy).
How much do Ozempic and Zepbound cost?
Pricing last verified April 2026. We update pricing data monthly.
| Ozempic | Zepbound | |
|---|---|---|
| List price (no savings) | ~$968/mo | ~$1,059/mo |
| LillyDirect / manufacturer self-pay | Not applicable | $299/mo (through Dec 2026) |
| With commercial insurance (T2D) | Often covered; $25–$150 copay | Not indicated for T2D |
| With commercial insurance (weight loss) | Not covered (off-label) | Covered by growing number of plans; prior auth required |
| Medicare Part D | Covered for T2D | Expanding coverage; bridge program expected 2026 |
| Compounded semaglutide (telehealth) | $129–$199/mo | N/A |
| Compounded tirzepatide (telehealth) | N/A | $349–$399/mo |
Zepbound's LillyDirect program ($299/month through December 2026) changes the out-of-pocket math: patients paying cash for weight loss treatment can access Zepbound at roughly $300/month, less than Ozempic's list price without insurance.
Compounded options: The FDA has issued enforcement actions against compounding pharmacies producing semaglutide and tirzepatide (30+ warning letters issued in early 2026). Remaining compounded options carry increasing regulatory risk. For context, see our compounded semaglutide comparison guide.
What are the side effects of Ozempic vs Zepbound?
Both drugs cause similar GI-related side effects, but Zepbound shows lower nausea rates in clinical trials.
| Side Effect | Ozempic/Semaglutide | Zepbound/Tirzepatide (15mg) |
|---|---|---|
| Nausea | ~20–44% (dose-dependent) | ~33% |
| Diarrhea | ~8–30% | ~23% |
| Vomiting | ~5–24% | ~13% |
| Constipation | ~3–24% | ~21% |
| Decreased appetite | Common | ~28% |
GI side effects for both drugs are worst during dose escalation and typically improve over 4–8 weeks at a stable dose. Tirzepatide's lower nausea rates in clinical trials may reflect the GIP receptor component, though individual responses vary significantly.
Both carry the same boxed warning: Risk of thyroid C-cell tumors observed in rodent studies. Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). The clinical relevance to humans is unknown based on current evidence.
Other risks for both: pancreatitis, gallbladder disease, acute kidney injury (typically secondary to GI-related dehydration).
Which telehealth platforms offer Ozempic vs Zepbound?
Most telehealth weight loss platforms prescribe compounded semaglutide or compounded tirzepatide rather than brand Ozempic or Zepbound — primarily because of cost. Brand drugs at $968–$1,059/mo are beyond what most self-pay telehealth patients will accept.
For semaglutide (compounded, similar to Ozempic's active ingredient):
- Henry Meds — compounded semaglutide from ~$199/mo
- Hims Weight Loss — transitioned to brand Wegovy distribution; compounded no longer offered
- Ro Body — brand semaglutide focus; compounded options limited post-2026 enforcement
For tirzepatide (compounded, same active ingredient as Zepbound):
- Mochi Health — compounded tirzepatide available; ~$399/mo
- Found — compounded tirzepatide option for eligible patients
- Henry Meds — compounded tirzepatide program
Brand Ozempic through telehealth requires a T2D diagnosis and insurance. Brand Zepbound is available through some telehealth platforms via LillyDirect partnerships, or on the Eli Lilly platform directly at $299/mo.
For a full breakdown of which providers offer which drugs and at what cost, see our GLP-1 telehealth provider comparison.
Who should choose Ozempic, and who should choose Zepbound?
Choose Ozempic if:
- You have type 2 diabetes — Ozempic is the FDA-indicated choice for T2D with cardiovascular benefit. Weight loss is an added benefit, not the primary goal.
- Your insurance covers Ozempic for T2D but not a weight-loss indication — Your physician may appropriately manage your diabetes with Ozempic even if weight loss is also desired.
- You're already established on Ozempic and it's working for both glycemic control and weight management.
Choose Zepbound if:
- Weight loss is your primary goal — Zepbound is the FDA-approved option for obesity, dosed and studied for that purpose.
- You want maximum weight loss — Tirzepatide produces significantly greater average weight loss than semaglutide based on all available trial data.
- You tried semaglutide and didn't get satisfactory results — Tirzepatide's dual mechanism may work for patients who don't respond adequately to GLP-1-only medications.
- You're paying out-of-pocket — LillyDirect's $299/mo self-pay program makes Zepbound competitive with compounded options.
- GI side effects are a concern — Tirzepatide shows lower nausea rates in clinical trials.
Consider compounded alternatives if:
- Neither brand is affordable without insurance, and you don't qualify for LillyDirect's self-pay program.
- You understand the regulatory landscape — Compounded options are available but carry increasing legal and quality uncertainty in 2026. Review our compounded vs brand GLP-1 comparison before choosing this path.
For additional semaglutide-specific alternatives, see our Ozempic alternatives guide.
How We Evaluated
This comparison is based on:
- FDA-approved prescribing information and product labeling for Ozempic (semaglutide) and Zepbound (tirzepatide)
- Published clinical trial data: STEP series (semaglutide), SURMOUNT series (tirzepatide), SURMOUNT-5 head-to-head
- Current manufacturer list prices and savings program documentation (verified April 2026)
- Telehealth provider website review for active drug availability (April 2026)
- Telehealth Ally editorial policies prohibit revenue-based ranking or provider compensation influencing comparisons
Frequently Asked Questions
Is Ozempic or Zepbound better for weight loss?
Zepbound (tirzepatide) produces more weight loss than Ozempic (semaglutide) in clinical trials. Tirzepatide achieved 20.2% mean weight loss versus 13.7% for semaglutide in the head-to-head SURMOUNT-5 trial. Zepbound is also FDA-approved specifically for obesity, while Ozempic is approved for type 2 diabetes only — weight loss is off-label for Ozempic.
What is the difference between Ozempic and Zepbound?
Ozempic contains semaglutide, a GLP-1 receptor agonist approved for type 2 diabetes. Zepbound contains tirzepatide, a dual GLP-1/GIP receptor agonist approved for chronic weight management. The two drugs work differently, are approved for different conditions, and have different dosing schedules. Tirzepatide's dual mechanism produces greater average weight loss than semaglutide.
Can I switch from Ozempic to Zepbound?
Yes, switching is possible and some patients do this when Ozempic doesn't produce sufficient weight loss, or when transitioning from T2D management to an obesity indication. Most providers restart from the lowest tirzepatide dose (2.5mg) and titrate up to minimize GI side effects during the transition. Discuss your specific clinical history with your prescriber before switching.
How much does Zepbound cost compared to Ozempic?
Ozempic's list price is approximately $968/month. Zepbound's list price is approximately $1,059/month, but LillyDirect offers a self-pay program at $299/month through December 2026. With insurance, Ozempic is more reliably covered (for T2D), while Zepbound coverage for weight management varies by plan.
Does insurance cover Ozempic and Zepbound?
Ozempic is widely covered for type 2 diabetes. Zepbound coverage for weight management varies — an increasing number of commercial plans cover it, but prior authorization is almost always required. Medicare coverage for Zepbound is expanding through the 2026 bridge program. Neither is typically covered for off-label use.
Is it worth switching from Ozempic to Zepbound for weight loss?
For patients using Ozempic off-label for weight loss who want better results, switching to Zepbound is often clinically appropriate. Tirzepatide produces nearly 50% greater relative weight loss than semaglutide in direct comparison. Whether switching makes financial sense depends on your insurance coverage and access to the LillyDirect self-pay program.
Which GLP-1 has fewer side effects, Ozempic or Zepbound?
Tirzepatide (Zepbound) shows lower nausea rates in clinical trials (33% at 15mg vs. 44% for semaglutide 2.4mg). Both drugs have similar GI side effect profiles overall. Side effects for both are worst during dose escalation and improve over time at a stable dose.
Related Resources
- Ozempic vs Wegovy — Comparing two semaglutide products from Novo Nordisk
- Mounjaro vs Zepbound — How Zepbound differs from its diabetes sibling
- Semaglutide vs Tirzepatide — Full mechanism and trial comparison
- Ozempic Weight Loss Results — What to realistically expect from semaglutide
- GLP-1 Telehealth Providers — Platforms offering Ozempic, Zepbound, and compounded alternatives
- GLP-1 Cost & Insurance FAQ — Full pricing and coverage breakdown
Where to Get These Medications
Compare providers offering GLP-1 medications.
Related Guides
Does Medicare Cover Ozempic? What You Need to Know in 2026
Does Medicare cover Ozempic in 2026? Yes for diabetes, no for weight loss. Learn about Part D coverage rules, costs, prior authorization, and cheaper alternatives.
Read guide →Generic Ozempic & Semaglutide: Timeline, Patents, and What to Expect
When will generic semaglutide (Ozempic) be available in the US? Patent landscape, international generics at $3/month, biosimilar timeline, and what you can do now to save.
Read guide →How Long Does Ozempic Take to Work? (Wegovy & Tirzepatide Too)
Ozempic and Wegovy typically suppress appetite within 1–2 weeks of starting. Meaningful weight loss appears around weeks 4–8. Full results at the highest dose take 12–16+ months. Here is the precise timeline, and what to do if nothing is happening.
Read guide →How to Get Ozempic Online in 2026: Step-by-Step Guide
Step-by-step guide to getting semaglutide online in 2026 — eligibility, telehealth providers, pricing, brand vs compounded, Hims brand-only status, orforglipron option, and red flags to avoid.
Read guide →